Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet's disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial

医学 阿达木单抗 白塞病 葡萄膜炎 不利影响 临床试验 疾病 英夫利昔单抗 随机对照试验 外科 内科学 免疫学
作者
Zhenyu Zhong,Dan Deng,Yu Gao,Qingqing Bu,Lingyu Dai,Xiaojie Feng,Chong Tang,Xiang Luo,Yao Wang,Chunjiang Zhou,Guannan Su,Peizeng Yang
出处
期刊:The Lancet Rheumatology [Elsevier BV]
卷期号:6 (11): e780-e790 被引量:39
标识
DOI:10.1016/s2665-9913(24)00194-2
摘要

SummaryBackgroundData from head-to-head trials of immunomodulatory therapies for Behçet's disease are scarce. We aimed to compare the efficacy and safety of ciclosporin, interferon alfa-2a, and adalimumab, each combined with corticosteroids, in preventing uveitis relapse in patients with severe Behçet's disease.MethodsWe did a randomised, open-label, assessor-masked, head-to-head trial at a large, specialised uveitis centre in Chongqing, China. Patients aged 18 years or older with severe Behçet's disease uveitis on corticosteroids and naive to anti-TNF therapy were eligible. Patients were randomly assigned in a 1:1:1 ratio to ciclosporin (2–5 mg/kg per day orally), interferon alfa-2a (3 million IU per day subcutaneously), or adalimumab (40 mg every 2 weeks subcutaneously), each combined with a tapering dose of corticosteroids with subsequent dose adjustments. The primary outcome was the annualised relapse rate of uveitis, assessed in the full analysis set (all randomly assigned patients with at least one post-baseline assessment). The non-inferiority margin of difference between the interferon alfa-2a and adalimumab groups was set to 1·0 for the primary outcome. Safety was assessed in all patients who received at least one dose of trial drugs. Individuals with lived experience of Behçet's disease uveitis were involved in the trial design and implementation. This study is registered with Chinese Clinical Trial Registry, ChiCTR2000031637. The trial is ongoing, but is closed to new participants.FindingsBetween May 12, 2020, and Feb 22, 2022, a total of 270 patients (mean age 38·1 years [SD 9·8]; 213 [79%] men, 57 [21%] women; 270 [100%] east Asian ethnicity) were randomly assigned to ciclosporin, interferon alfa-2a, or adalimumab (n=90 in each group); 261 patients were included in the full analysis set. For the primary outcome, the least-squares mean was 1·84 (95% CI 1·40 to 2·44) with ciclosporin, 1·44 (1·10 to 1·89) with interferon alfa-2a, and 0·95 (0·64 to 1·40) with adalimumab. The annualised relapse rate was significantly higher in patients receiving ciclosporin than in those receiving adalimumab (least-squares mean difference 0·90 [95% CI 0·27 to 1·53]; p=0·0054 for superiority). The least-squares mean difference between interferon alfa-2a and adalimumab was 0·50 (–0·04 to 1·04), which did not meet non-inferiority criteria (p=0·034 for non-inferiority). The primary outcome did not differ substantially between interferon alfa-2a and ciclosporin (least-squares mean difference –0·40 [–1·05 to 0·25]; p=0·23 for superiority). Serious adverse events were reported in 12 (13%) of 90 patients on ciclosporin plus corticosteroids, eight (9%) of 90 patients on interferon alfa-2a plus corticosteroids, and seven (8%) of 90 patients on adalimumab plus corticosteroids. There were no treatment-related deaths.InterpretationAdalimumab plus corticosteroids was superior to ciclosporin plus corticosteroids with respect to uveitis relapse rate in patients with severe Behçet's disease naive to anti-TNF therapy, and interferon alfa-2a plus corticosteroids was not found to be non-inferior to adalimumab plus corticosteroids or superior to ciclosporin plus corticosteroids.FundingNational Natural Science Foundation of China Key Program, Major Program of Medical Science and Technology Project of Health Commission of Henan Province, Chongqing Key Laboratory of Ophthalmology, and China National Postdoctoral Program for Innovative Talents.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
安吉拉学术记完成签到,获得积分10
3秒前
nnn完成签到,获得积分10
3秒前
3秒前
桐桐的应助被ahe采纳,获得10
4秒前
6秒前
7秒前
8秒前
8秒前
阿白发布了新的文献求助10
8秒前
Zhaoyu完成签到,获得积分10
8秒前
9秒前
漂亮的大神完成签到,获得积分20
9秒前
闪亮的屁灯完成签到 ,获得积分10
10秒前
daisyyy完成签到 ,获得积分10
11秒前
11秒前
一路向北完成签到,获得积分10
12秒前
13秒前
13秒前
ZZZ完成签到 ,获得积分20
14秒前
whatislove发布了新的文献求助20
14秒前
14秒前
科研通AI6.2的应助被675675采纳,获得10
14秒前
余香的应助被青年才俊采纳,获得30
17秒前
wanci的应助被青年才俊采纳,获得10
17秒前
Maestro_S的应助被青年才俊采纳,获得10
17秒前
飘扬雄风发布了新的文献求助10
17秒前
木子完成签到 ,获得积分10
20秒前
汉堡包的应助被WWWJ采纳,获得10
20秒前
依123完成签到 ,获得积分10
22秒前
古古完成签到,获得积分10
22秒前
22秒前
22秒前
22秒前
哆小咪完成签到 ,获得积分10
23秒前
attention完成签到,获得积分10
24秒前
shenjingjing完成签到 ,获得积分10
24秒前
24秒前
小吴完成签到,获得积分10
25秒前
流星雨完成签到,获得积分10
25秒前
元狩完成签到,获得积分10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181767
求助须知:如何正确求助?哪些是违规求助? 9571480
关于积分的说明 21818225
捐赠科研通 7778030
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479598